Prospective Multi-centre Studies of Prognostic Factors in Castration Resistant PROState Cancer Treated With Abiraterone

Trial Profile

Prospective Multi-centre Studies of Prognostic Factors in Castration Resistant PROState Cancer Treated With Abiraterone

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Abiraterone acetate (Primary)
  • Indications Prostate cancer
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms PROSABI
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2018.
    • 04 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top